23:35 , Dec 15, 2017 |  BC Extra  |  Financial News

Financial tracks: Accelerator Life Science Partners

Investment firm Accelerator Life Science Partners (Seattle, Wash.), formerly Accelerator Corp., hired Kendall Mohler as chief development officer and Ian Howes as CFO. Mohler was CSO and SVP of research at Juno Therapeutics Inc. (NASDAQ:JUNO)....
21:20 , Sep 13, 2017 |  BioCentury  |  Emerging Company Profile

Not PGE2's first Rodeo

Rodeo Therapeutics Corp. is boosting prostaglandin E2 production within cells rather than delivering it systemically to promote tissue regeneration without the side effects that have dogged the molecule in the past. Tissues up-regulate prostaglandin E2...
15:09 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Novocure evaluting Optune in combination with marizomib and temozolomide

Celgene Corp. (NASDAQ:CELG) modified an ongoing Phase Ib trial of IV marizomib ( NPI-0052 ) in combination with temozolomide and radiotherapy in about 48 newly diagnosed patients with grade IV malignant gliomas to include a...
15:08 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Marizomib, Temozolomide combination trial expanded to include Optune from Novocure

Celgene Corp. (NASDAQ:CELG) modified an ongoing Phase Ib trial of IV marizomib (NPI-0052) in combination with temozolomide and radiotherapy in about 48 newly diagnosed patients with grade IV malignant gliomas to include a 12-patient cohort...
17:51 , Jul 28, 2017 |  BC Week In Review  |  Financial News

Accelerator leads Rodeo's series A

Regenerative therapy company Rodeo Therapeutics Corp. (Seattle, Wash.) raised $5.9 million on July 25 in a series A round led by Accelerator Corp. (Seattle, Wash.). Also participating were AbbVie Ventures, Alexandria Venture Investments, ARCH Venture,...
13:28 , Jul 25, 2017 |  BC Extra  |  Financial News

Accelerator leads Rodeo's series A round

Newly launched Rodeo Therapeutics Corp. (Seattle, Wash.) raised $5.9 million in a series A round led by Accelerator Corp. (Seattle, Wash.). Also participating were AbbVie Ventures, Alexandria Venture Investments, ARCH Venture, Eli Lilly and Co....
00:38 , Apr 28, 2017 |  BC Innovations  |  Finance

Hatching VC incubators

While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it. Indeed, a collection of VCs...
22:48 , Mar 30, 2017 |  BioCentury  |  Emerging Company Profile

Resisting resistance

While many companies are attempting to counteract mutations in cancer that result in resistance, ApoGen Biotechnologies Inc. is instead targeting a mechanism that causes resistance mutations to develop. The approach could prolong responses to cancer...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
01:43 , Dec 30, 2016 |  BC Week In Review  |  Company News

Triphase, Celgene deal

Triphase granted Celgene an option to acquire all assets relating to lymphoma candidate TRPH-222 ( CD22-4AP ). If Celgene exercises its option, it will be responsible for development and commercialization of the product, and Triphase...